BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 9567363)

  • 1. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
    van Holten-Verzantvoort AT; Papapoulos SE
    Medicina (B Aires); 1997; 57 Suppl 1():109-13. PubMed ID: 9567363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
    Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
    N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
    Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials in metastatic breast cancer to bone: past--present--future.
    Body JJ
    Can J Oncol; 1995 Dec; 5 Suppl 1():16-27. PubMed ID: 8853520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bisphosphonates in breast cancer.
    Coleman RE
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current use of bisphosphonates in clinical oncology].
    Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
    Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New generation of bisphosphonates: broad clinical utility in breast and prostate cancer.
    Rosen LS
    Oncology (Williston Park); 2004 May; 18(5 Suppl 3):26-32. PubMed ID: 15202585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study.
    Hultborn R; Gundersen S; Ryden S; Holmberg E; Carstensen J; Wallgren UB; Killany S; Andreassen L; Carlsson G; Fahl N; Hatschek T; Sommer HH; Hessman Y; Hornmark-Stenstam B; Johnsborg S; Klepp R; Laino R; Niklasson LG; Rudenstam CM; Sundbeck A; Söderberg M; Tejler G
    Anticancer Res; 1999; 19(4C):3383-92. PubMed ID: 10629624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates for the prevention of bone metastases.
    Coleman RE
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):43-9. PubMed ID: 12584694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Bisphosphonates in the treatment and prevention of bone metastases].
    Hoekman K; van Holten-Verzantvoort AT; Pinedo HM
    Ned Tijdschr Geneeskd; 1997 Nov; 141(46):2217-22. PubMed ID: 9550782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates and metastatic breast carcinoma.
    Lipton A
    Cancer; 2003 Feb; 97(3 Suppl):848-53. PubMed ID: 12548585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of bone metastases in breast cancer patients.
    Petrut B; Simmons C; Broom R; Trinkaus M; Clemons M
    Expert Opin Pharmacother; 2008 Apr; 9(6):937-45. PubMed ID: 18377337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bisphosphonate therapy for patients with breast carcinoma.
    Plunkett TA; Rubens RD
    Cancer; 2003 Feb; 97(3 Suppl):854-8. PubMed ID: 12548586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bisphosphonates as adjuvant therapy for operable breast cancer.
    Powles T; McCroskey E; Paterson A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6301s-6304s. PubMed ID: 17062718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.